Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Agilent Technologies    A

AGILENT TECHNOLOGIES

(A)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Agilent Technologies : 285.7 KB

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/11/2019 | 08:43am EDT

Agilent to Acquire BioTek Instruments Inc.

July 11, 2019

Safe Harbor

This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company's goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth opportunities, new products and solutions, customer service and innovation plans, financial condition and considerations, share repurchases, dividends, the markets the company sells into, operations, manufacturing site plans and tax rates) that involve risks and uncertainties that could cause results of Agilent to differ materially from management's

current expectations. The words "anticipate," "plan," "estimate," "expect," "intend," "will," "should," "forecast," "project" and similar expressions, as they relate to the company, are intended to identify forward-looking statements.

In addition, other risks that the company faces in running its operations include the ability to execute successfully through business cycles; the ability to successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross margin pressures; the risk that our strategic and cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties on our markets and our ability to conduct business; the impact of currency exchange rates on our financial results; the ability to improve asset performance to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix, and other risks detailed in the company's filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended April 30, 2019.

The company assumes no obligation to update the information in these presentations. This presentation includes non-GAAP measures. Non-GAAP measures exclude primarily the impacts of amortization of intangibles, acquisition and integration costs, transformational initiatives, and business exits and divestitures. We also exclude any tax benefits that are not directly related to ongoing operations and which are either isolated or are not expected to occur again with any regularity or predictability, including

the impact of the 2017 Tax Act. With respect to the company's guidance, most of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy. Accordingly, no

reconciliation to GAAP amounts has been provided.

2

July 11, 2019

Strategic Rationale for the deal

  • A leading producer of instrumentation and assays used for analyzing live cells - Imaging and Microscopy Systems, Microplate Readers and Robotic Systems
  • A talented global team of 500 people with an impressive track record of innovation and business performance
  • Attractive high-growth markets
    • Immuno-therapiesdriving demand for live- cell real-time analysis

3

July 11, 2019

  • Complementary to Agilent's capabilities and position in cell analysis; the combined companies will lead live-cell analysis - an area of strategic M&A focus
  • Opportunity to innovate, integrate and simplify live-cell,real-time cell analysis workflows used in immunotherapy, biologics research and drug development
  • Outstanding cultural and technology fit proven through the on-going partnership between Agilent and BioTek

Transaction highlights

Purchase Price: $1,165M ($1,050M - net of anticipated tax benefits), representing approx. 22x FY19 EBIDTA (1)

ROIC(2): Expect to achieve HSD in 5 years

Margins: In line with Agilent margins

Adjusted EPS(3): Accretive from year 1, expect $0.02-$0.04 for FY20 (inclusive of financing), and compounding growth thereafter

Financing: Mix of Cash and Credit Facilities

  1. : EBIDTA - Earnings before Interest, Depreciation, Tax and Amortization
  2. : ROIC - Return on Invested Capital
  3. : EPS - Earnings per Share, presented on Non-GAAP basis
  4. : CAGR : Compounded Annual Growth Rate

4July 11, 2019

$162M

12%

FY18 Revenue

CAGR(4) over last three years

Other, 4%

Asia,

10%

Govt, 10%

China,

Pharma and

16%

BioTech,

45%

Academic

Europe,

Research,

18%

Americas, 56%

41%

Disclaimer

Agilent Technologies Inc. published this content on 11 July 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 July 2019 12:42:02 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AGILENT TECHNOLOGIES
08/19AGILENT TECHNOLOGIES : NUS, Agilent, and NUH launch new translational R&D hub to..
AQ
08/19AGILENT TECHNOLOGIES : OFS Academy Receives Learning!100 Award for Third Consecu..
AQ
08/19AGILENT TECHNOLOGIES : OFS Academy Receives Learning!100 Award for Third Consecu..
BU
08/19AGILENT TECHNOLOGIES : NUS, Agilent, and NUH Launch New Translational R&D Hub to..
BU
08/16AGILENT TECHNOLOGIES INC : Other Events (form 8-K)
AQ
08/16AGILENT TECHNOLOGIES : Presents Thought Leader Award to Professor Gang Yu; Influ..
AQ
08/16AGILENT TECHNOLOGIES : Introduces Revolutionary Real-Time Cell Analyzer; Multipl..
AQ
08/15Walmart and Agilent rise; Tapestry and General Electric fall
AQ
08/15AGILENT TECHNOLOGIES : Up 8.3% After Earnings, Guidance
DJ
08/15Agilent Up Over 8%, on Pace for Largest Percent Increase Since November 2013 ..
DJ
More news
Financials (USD)
Sales 2019 5 123 M
EBIT 2019 1 183 M
Net income 2019 1 085 M
Finance 2019 26,6 M
Yield 2019 0,91%
P/E ratio 2019 20,8x
P/E ratio 2020 23,4x
EV / Sales2019 4,34x
EV / Sales2020 4,01x
Capitalization 22 239 M
Chart AGILENT TECHNOLOGIES
Duration : Period :
Agilent Technologies Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AGILENT TECHNOLOGIES
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 81,29  $
Last Close Price 71,74  $
Spread / Highest target 28,2%
Spread / Average Target 13,3%
Spread / Lowest Target -8,00%
EPS Revisions
Managers
NameTitle
Michael R. McMullen President, Chief Executive Officer & Director
Boon Hwee Koh Non-Executive Chairman
Kristin Giffin Vice President-Operations, Quality & Support
Robert W. McMahon Chief Financial Officer & Senior Vice President
Darlene J. S. Solomon Chief Technology Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
AGILENT TECHNOLOGIES6.34%22 382
THERMO FISHER SCIENTIFIC23.41%111 440
DANAHER CORPORATION36.07%100 661
BOSTON SCIENTIFIC CORPORATION20.26%59 271
INTUITIVE SURGICAL4.67%57 774
EDWARDS LIFESCIENCES CORPORATION44.94%46 125